| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $63,800 | 1 | 50 |
Sells | $96,145 | 1 | 50 |
| Levy Richard S | director | 1 | $63,800 | 0 | $0 | $63,800 |
| Zummo Jacqueline | Chf Scientific Operations Off | 0 | $0 | 1 | $96,145 | $-96,145 |
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Over the last 12 months, insiders at Protara Therapeutics, Inc. have bought $63,800 and sold $96,145 worth of Protara Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Protara Therapeutics, Inc. have bought $364,346 and sold $629,428 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Levy Richard S (director) — $63,800.
The last purchase of 20,000 shares for transaction amount of $63,800 was made by Levy Richard S (director) on 2025‑05‑14.
| 2025-05-14 | Levy Richard S | director | 20,000 0.0528% | $3.19 | $63,800 | +51.12% | ||
| 2025-03-26 | Sale | Zummo Jacqueline | Chf Scientific Operations Off | 21,224 0.0577% | $4.53 | $96,145 | -7.06% | |
| 2024-09-12 | Sale | Opaleye Management Inc. | 10 percent owner | 126,301 0.6048% | $1.71 | $215,836 | +87.57% | |
| 2024-09-11 | Sale | Opaleye Management Inc. | 10 percent owner | 32,600 0.1566% | $1.71 | $55,880 | +90.88% | |
| 2024-09-10 | Sale | Opaleye Management Inc. | 10 percent owner | 25,500 0.1264% | $1.77 | $45,110 | +87.57% | |
| 2024-09-09 | Sale | Opaleye Management Inc. | 10 percent owner | 36,492 0.1821% | $1.89 | $69,141 | +76.36% | |
| 2024-07-16 | Sale | Opaleye Management Inc. | 10 percent owner | 11,396 0.0691% | $2.44 | $27,828 | +31.67% | |
| 2024-07-11 | Sale | Opaleye Management Inc. | 10 percent owner | 47,993 0.2866% | $2.40 | $115,346 | +34.83% | |
| 2024-07-10 | Sale | Opaleye Management Inc. | 10 percent owner | 18,061 0.1036% | $2.31 | $41,685 | +36.58% | |
| 2024-07-09 | Sale | Opaleye Management Inc. | 10 percent owner | 8,497 0.0467% | $2.21 | $18,811 | +48.12% | |
| 2024-07-01 | Sale | Opaleye Management Inc. | 10 percent owner | 8,288 0.0437% | $2.12 | $17,598 | +50.48% | |
| 2024-06-28 | Sale | Opaleye Management Inc. | 10 percent owner | 17,994 0.0927% | $2.07 | $37,334 | +51.44% | |
| 2024-06-27 | Sale | Opaleye Management Inc. | 10 percent owner | 46,574 0.2613% | $2.26 | $105,169 | +44.93% | |
| 2024-06-25 | Sale | Opaleye Management Inc. | 10 percent owner | 12,725 0.0665% | $2.26 | $28,734 | +49.76% | |
| 2024-05-31 | Sale | Opaleye Management Inc. | 10 percent owner | 5,824 0.0292% | $2.90 | $16,895 | +2.85% | |
| 2024-05-30 | Sale | Opaleye Management Inc. | 10 percent owner | 9,230 0.0454% | $2.94 | $27,113 | -1.55% | |
| 2024-05-22 | Sale | Opaleye Management Inc. | 10 percent owner | 9,800 0.0481% | $3.02 | $29,596 | -6.35% | |
| 2024-05-21 | Sale | Opaleye Management Inc. | 10 percent owner | 33,000 0.1671% | $3.06 | $100,838 | -4.44% | |
| 2024-05-17 | Sale | Opaleye Management Inc. | 10 percent owner | 70,885 0.3032% | $3.25 | $230,326 | -9.39% | |
| 2024-05-10 | Sale | Opaleye Management Inc. | 10 percent owner | 151,700 0.7648% | $3.11 | $472,424 | -6.67% |
| Zummo Jacqueline | Chf Scientific Operations Off | 98861 0.2562% | $583,279.90 | 0 | 1 | |
| Levy Richard S | director | 51000 0.1322% | $300,900.00 | 1 | 0 | |
| O'Leary Brendan | director | 1387198 3.5948% | $8.18M | 1 | 0 | |
| Abingworth LLP | 10 percent owner | 950000 2.4618% | $5.61M | 1 | 0 | |
| Haines Timothy | 950000 2.4618% | $5.61M | 1 | 0 | ||
| Shefferman Jesse | CEO and President | 879441 2.279% | $5.19M | 1 | 0 | <0.0001% |
| Pharmstandard International S.A. | 10 percent owner | 600000 1.5548% | $3.54M | 1 | 0 | |
| Kobyzev Dmitry | 600000 1.5548% | $3.54M | 1 | 0 | ||
| Marshall Randall | 585600 1.5175% | $3.46M | 0 | 27 | ||
| Birner Hubert | 300000 0.7774% | $1.77M | 1 | 0 | ||
| TVM Life Science Ventures VI GmbH & Co KG | 10 percent owner | 300000 0.7774% | $1.77M | 1 | 0 | |
| Freund John Gordon | 200000 0.5183% | $1.18M | 1 | 1 | ||
| Skyline Venture Partners Qualified Purchaser Fund IV L P | 10 percent owner | 200000 0.5183% | $1.18M | 1 | 1 | |
| BESHAR LUKE M | 198000 0.5131% | $1.17M | 3 | 0 | <0.0001% | |
| Flynn James E | director | 197424 0.5116% | $1.16M | 2 | 1 | |
| Burke Steven Keith | SVP and Chief Medical Officer | 117535 0.3046% | $693,456.50 | 1 | 0 | |
| Opaleye Management Inc. | 10 percent owner | 45000 0.1166% | $265,500.00 | 15 | 20 | <0.0001% |
| Olivo Martin Sebastian | Chief Medical Officer | 14344 0.0372% | $84,629.60 | 1 | 0 | <0.0001% |
| Eldridge, George Arthur | Sr VP, CFO, Treasr, Asst Secy | 1545 0.004% | $9,115.50 | 2 | 0 | |
| Davis Blaine | Chief Financial Officer | 1481 0.0038% | $8,737.90 | 1 | 0 | <0.0001% |
| NOYES TIMOTHY P | President and CEO | 0 0% | $0 | 0 | 5 | |
| Gottlieb Daniel Philip | VP Marketing & Bus Development | 0 0% | $0 | 0 | 1 |
$8,708,580 | 93 | -5.38% | $237.37M | |
$87,639,490 | 62 | 18.37% | $288.78M | |
$3,668,031 | 23 | 2.05% | $262.83M | |
Protara Therapeutics, Inc. (TARA) | $6,915,275 | 21 | -32.61% | $227.68M |
$22,365,077 | 19 | -27.47% | $271.2M | |
$245,302 | 15 | -4.08% | $286.66M | |
$170,425 | 10 | -16.01% | $243.93M | |
$145,296,407 | 8 | -0.98% | $216.84M | |
$119,804,612 | 8 | -17.22% | $286.94M | |
$5,905,507 | 7 | 2.69% | $215.11M | |
$272,982 | 6 | -28.53% | $227.31M | |
$8,286,963 | 6 | 3.09% | $212.13M | |
$556,839 | 5 | 13.42% | $225.32M | |
$20,729,984 | 5 | 51.71% | $215.3M | |
$32,007,657 | 4 | -45.65% | $223.76M | |
$6,049,986 | 4 | -8.38% | $231.77M | |
$16,003,671 | 3 | 55.38% | $219.94M | |
$32,289,200 | 3 | -5.46% | $220.73M | |
$37,067 | 3 | -89.81% | $242.88M |
| Increased Positions | 76 | +124.59% | 15M | +55.72% |
| Decreased Positions | 24 | -39.34% | 1M | -3.88% |
| New Positions | 31 | New | 6M | New |
| Sold Out Positions | 8 | Sold Out | 539,694 | Sold Out |
| Total Postitions | 113 | +85.25% | 40M | +51.83% |
| Janus Henderson Group Plc | $22,765.00 | 8.14% | 4.23M | +128,711 | +3.14% | 2025-09-30 |
| Blackrock, Inc. | $11,994.00 | 4.29% | 2.23M | +85,488 | +3.99% | 2025-09-30 |
| Velan Capital Investment Management Lp | $11,508.00 | 4.11% | 2.14M | 0 | 0% | 2025-09-30 |
| Blackstone Inc. | $10,274.00 | 3.67% | 1.91M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $10,244.00 | 3.66% | 1.9M | +102,176 | +5.67% | 2025-09-30 |
| Acorn Capital Advisors, Llc | $9,426.00 | 3.37% | 1.75M | 0 | 0% | 2025-09-30 |
| Catalio Capital Management, Lp | $8,074.00 | 2.89% | 1.5M | -125,577 | -7.72% | 2025-09-30 |
| Integral Health Asset Management, Llc | $7,532.00 | 2.69% | 1.4M | 0 | 0% | 2025-09-30 |
| Ubs Group Ag | $4,536.00 | 1.62% | 843,074 | -292,693 | -25.77% | 2025-09-30 |
| 5Am Venture Management, Llc | $4,304.00 | 1.54% | 800,000 | 0 | 0% | 2025-09-30 |